
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Reevaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients
A Systematic Review and Meta-analysis</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "â–¶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Reevaluating the Role of Proton Pump Inhibitors After Endoscopic Band Ligation of Esophageal Varices in Cirrhotic Patients</strong><br><em>A Systematic Review and Meta-analysis</em></summary>
            <div>
                <ul><li>- <b>Journal:</b> American Journal of Gastroenterology</li><li>- <b>Publication Date:</b> Publish Ahead of Print (as of Jan 2025 search)</li><li>- <b>DOI:</b> 10.14309/ajg.0000000000003800</li></ul>
                
        <details>
            <summary><strong>ðŸ’¡ Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the 6-week mortality rate for variceal bleeding?</li><li>- What is the average time to bleed from a post-EBL ulcer?</li><li>- In the Trial Sequential Analysis, what was the Required Information Size (RIS) to determine PPI efficacy?</li><li>- In the study by Lashen et al., PPI use significantly reduced which adverse event?</li><li>- What is the rebleeding rate without endoscopic treatment?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Introduction & Background</strong></summary>
            <div>
                <ul><li>- This systematic review and meta-analysis aims to determine if <b>Proton Pump Inhibitor (PPI)</b> use is associated with improved outcomes after <b>Endoscopic Band Ligation (EBL)</b> in cirrhotic patients.</li></ul>
                
        <details>
            <summary><strong>Burden of Liver Cirrhosis</strong></summary>
            <div>
                <ul><li>- A critical global health concern with increasing prevalence.</li><li>- Affects an estimated <q>112 million</q> individuals worldwide.</li><li>- Results in <q>1.48 million</q> deaths annually (2019 data).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Gastroesophageal Varices (GEVs)</strong></summary>
            <div>
                <ul><li>- A major complication of portal hypertension in advanced liver disease.</li></ul>
                
        <details>
            <summary><strong>Prevalence</strong></summary>
            <div>
                <ul><li>- Present in <q><b>30%-40%</b></q> of patients with <u>compensated</u> cirrhosis.</li><li>- Present in <q><b>48%-85%</b></q> of patients with <u>decompensated</u> cirrhosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Bleeding Risk & Mortality</strong></summary>
            <div>
                <ul><li>- Annual bleeding risk: <q><b>10%-15%</b></q>.</li><li>- 6-week mortality rate post-bleed: <q><b>15-20%</b></q>.</li><li>- Rebleeding rate without endoscopic treatment: up to <q><b>60%</b></q>, with mortality reaching <q><b>33%</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of GEVs</strong></summary>
            <div>
                <ul><li>- Focus on primary and secondary prophylaxis to mitigate bleeding risk.</li></ul>
                
        <details>
            <summary><strong>Pharmacological Therapy</strong></summary>
            <div>
                <ul><li>- <b>Non-selective beta-blockers (NSBBs)</b> are central to management.</li><li>- <u>Preferred agent</u> per BAVENO VII consensus: <q><b>Carvedilol</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endoscopic Variceal Ligation (EVL/EBL)</strong></summary>
            <div>
                <ul><li>- <b>Primary Prophylaxis:</b> Recommended for high-risk varices in patients intolerant to NSBBs.</li><li>- <b>Secondary Prophylaxis:</b> Combination of <u>EVL + NSBBs</u> is the standard of care, reducing rebleeding by <q>27%-38%</q> compared to monotherapy.</li><li>- <b>Acute Bleeding:</b> EVL is the <u>cornerstone</u> of endoscopic therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>The PPI Controversy Post-EBL</strong></summary>
            <div>
                <ul><li>- Ulceration at ligation sites is a known cause of rebleeding.</li></ul>
                
        <details>
            <summary><strong>Rationale for Use</strong></summary>
            <div>
                <ul><li>- PPIs are widely used to promote mucosal healing and prevent ulcer-related bleeding.</li><li>- Periprocedural administration reported in up to <q>80%</q> of patients undergoing prophylactic EBL.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Concerns & Inconsistent Data</strong></summary>
            <div>
                <ul><li>- Efficacy in variceal bleeding is controversial.</li><li>- Bleeding is driven by <b>portal hypertension</b>, not acid-related injury.</li><li>- Potential increased risks in cirrhosis: <q>spontaneous bacterial peritonitis, C. difficile infection, pneumonia, and hepatic encephalopathy</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Guideline Divergence</strong></summary>
            <div>
                <ul><li>- <b>ASGE (older):</b> Supported use.</li><li>- <b>ESGE & Baveno VII (recent):</b> Provide <u>weak recommendations against</u> routine PPI use after acute variceal bleeding management.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Meta-Analysis Overview</strong></summary>
            <div>
                <ul><li>- <b>11 studies</b> included (4 RCTs, 7 observational).</li><li>- Total of <b>7,459 cirrhotic patients</b> undergoing EBL.</li></ul>
                
        <details>
            <summary><strong>Patient Demographics</strong></summary>
            <div>
                <ul><li>- Mean age: <q>55.5 years</q>.</li><li>- Sex: <q>75% male</q>.</li><li>- Mean MELD score: <q>16.8</q>.</li></ul>
                
        <details>
            <summary><strong>Child-Pugh Classification (n=5,865)</strong></summary>
            <div>
                <ul><li>- <b>Class A:</b> <q>47%</q></li><li>- <b>Class B:</b> <q>34%</q></li><li>- <b>Class C:</b> <q>19%</q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Primary Outcomes</strong></summary>
            <div>
                <ul><li>- <b>Post-EBL Ulcer Bleeding:</b> Bleeding with endoscopic proof of a post-banding ulcer as the source.</li><li>- <b>Post-EBL Bleeding (Overall):</b> Any clinical/endoscopic evidence of UGIB after EBL.</li><li>- <b>All-Cause Mortality:</b> Death from any cause.</li></ul>
                
        <details>
            <summary><strong>Follow-up Period</strong></summary>
            <div>
                <ul><li>- All primary outcomes were assessed within an <q>8-week</q> follow-up period.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Secondary Outcomes</strong></summary>
            <div>
                <ul><li>- Number and size of post-banding ulcers.</li><li>- Length of hospitalization.</li><li>- Adverse events (e.g., chest pain, dysphagia).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Key Findings & Results</strong></summary>
            <div>
                <ul><li>- The most rigorous analyses (adjusted observational data and RCTs) <b><u>did not show a statistically significant benefit</u></b> for PPI use in reducing bleeding or mortality.</li></ul>
                
        <details>
            <summary><strong>Post-EBL Bleeding (Overall)</strong></summary>
            <div>
                <ul><li>- Analysis of all 11 studies (n=7,459).</li></ul>
                
        <details>
            <summary><strong>Combined Unadjusted Analysis</strong></summary>
            <div>
                <ul><li>- Showed a statistically significant reduction in bleeding with PPIs.</li><li>- <b>OR:</b> <q>0.76</q> (95% CI, 0.62 - 0.92).</li><li>- <b>Finding Not Robust:</b> Became non-significant in leave-one-out analysis when the Hu et al. study was removed.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adjusted Observational Data</strong></summary>
            <div>
                <ul><li>- Pooled analysis of 5 studies (n=5,907).</li><li>- <b><u>No significant benefit</u></b> for PPIs.</li><li>- <b>OR:</b> <q>0.64</q> (95% CI, 0.33 - 1.23).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>RCTs Only (Highest Quality)</strong></summary>
            <div>
                <ul><li>- Pooled analysis of 4 RCTs (n=445).</li><li>- <b><u>No significant benefit</u></b> for PPIs.</li><li>- <b>RR:</b> <q>0.71</q> (95% CI, 0.39 - 1.30).</li></ul>
                
        <details>
            <summary><strong>Trial Sequential Analysis (TSA)</strong></summary>
            <div>
                <ul><li>- Confirmed that the cumulative RCT evidence is <b><u>underpowered</u></b>.</li><li>- Required Information Size (RIS) for a definitive conclusion: <q><b>2,501 patients</b></q>.</li><li>- Current cumulative sample size: <q>445 patients</q> (<q>17.8%</q> of RIS).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-EBL Ulcer Bleeding (Mechanistic Outcome)</strong></summary>
            <div>
                <ul><li>- This is the most specific outcome for evaluating PPI efficacy.</li></ul>
                
        <details>
            <summary><strong>Combined Unadjusted Analysis</strong></summary>
            <div>
                <ul><li>- Showed a significant reduction in ulcer bleeding with PPIs (OR 0.76).</li><li>- <b>Finding Not Robust:</b> Became non-significant when the Hu et al. study was removed.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>RCTs Only</strong></summary>
            <div>
                <ul><li>- <b>Within 8 weeks:</b> <u>No statistically significant effect</u> (RR <q>0.54</q>, 95% CI 0.25 - 1.16).</li><li>- <b>Within 2 weeks:</b> <u>No statistically significant effect</u> (RR <q>0.59</q>, 95% CI 0.27 - 1.27).</li><li>- The average time to bleed from a post-EBL ulcer is <q>11 days</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>All-Cause Mortality</strong></summary>
            <div>
                <ul><li>- Analysis of 6 studies (n=959).</li></ul>
                
        <details>
            <summary><strong>Combined Unadjusted Analysis</strong></summary>
            <div>
                <ul><li>- Showed a significant reduction in mortality with PPIs (OR <q>0.48</q>).</li><li>- <b>Finding Not Robust:</b> Became non-significant in leave-one-out sensitivity analysis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>RCTs Only</strong></summary>
            <div>
                <ul><li>- Pooled analysis of 3 RCTs (n=268).</li><li>- <b><u>No significant benefit</u></b> for PPIs.</li><li>- <b>RR:</b> <q>0.75</q> (95% CI, 0.23 - 2.53).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Secondary Outcomes Analysis</strong></summary>
            <div>
                <ul><li>- Findings were either non-significant or inconsistent.</li></ul>
                
        <details>
            <summary><strong>Length of Hospitalization</strong></summary>
            <div>
                <ul><li>- <b><u>No significant difference</u></b> between PPI and control groups.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Post-Banding Ulcer Size & Number</strong></summary>
            <div>
                <ul><li>- Data could not be meta-analyzed due to metric variability.</li></ul>
                
        <details>
            <summary><strong>Narrative Summary of 3 RCTs</strong></summary>
            <div>
                <ul><li>- <b>Ulcer Size:</b> Consistently and significantly <u>smaller</u> in the PPI group.</li><li>- <b>Ulcer Number:</b> <u>No significant difference</u> between groups.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adverse Events</strong></summary>
            <div>
                <ul><li>- Findings were inconsistent across studies.</li></ul>
                
        <details>
            <summary><strong>Chest Pain</strong></summary>
            <div>
                <ul><li>- Lashen et al: Incidence was <u>significantly lower</u> in the PPI group (<q>39.6% vs. 73.6%</q>).</li><li>- Shaheen et al: No significant difference.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Events</strong></summary>
            <div>
                <ul><li>- No significant difference in total adverse events, odynophagia, or dysphagia.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Discussion & Interpretation</strong></summary>
            <div>
                <ul><li>- The divergence in results suggests that apparent benefits in unadjusted analyses are likely driven by <b><u>residual confounding</u></b> rather than a true therapeutic effect.</li></ul>
                
        <details>
            <summary><strong>Pathophysiological Disconnect</strong></summary>
            <div>
                <ul><li>- GEV bleeding is driven by <b>portal hypertension</b>, not acid-related mucosal injury.</li><li>- EBL ulcers are <u>mechanically induced</u> and usually self-limiting.</li><li>- Reduced ulcer size with PPIs did not translate to a reduction in the clinically relevant outcome of rebleeding.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Limitations of the Evidence</strong></summary>
            <div>
                <ul><li>- The current body of evidence has significant limitations.</li></ul>
                
        <details>
            <summary><strong>Underpowered RCTs</strong></summary>
            <div>
                <ul><li>- The primary limitation is the small cumulative sample size in RCTs, making the evidence inconclusive.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Heterogeneity</strong></summary>
            <div>
                <ul><li>- Significant clinical heterogeneity across studies in:</li><li>- PPI type, dose, and duration.</li><li>- EBL indication (prophylaxis vs. emergency).</li><li>- Inclusion of non-specific bleeding events (e.g., recurrent variceal hemorrhage) dilutes any potential treatment effect.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Influence of a Single Study</strong></summary>
            <div>
                <ul><li>- The observational study by <b>Hu et al.</b> had a substantial statistical influence, making the overall pooled estimates for bleeding unstable and not robust.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Conclusion & Clinical Recommendation</strong></summary>
            <div>
                <ul><li>- The current evidence is <b><u>insufficient</u></b> to draw a definitive conclusion on the efficacy of PPIs after EBL.</li></ul>
                
        <details>
            <summary><strong>Clinical Takeaway</strong></summary>
            <div>
                <ul><li>- Given the <b>lack of strong supporting evidence</b> and the <b>potential for harm</b> (e.g., infections, HE), routine prophylactic PPI use after EBL <b><u>cannot be recommended</u></b> at this time.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Future Direction</strong></summary>
            <div>
                <ul><li>- <b>High-quality, adequately powered randomized trials</b> are urgently needed to resolve this important clinical uncertainty.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
